#solar energy #United Kingdom #Piramal Pharma #Morpeth #Morpeth Plant

Introduction to Sustainability Initiatives

In a significant step towards sustainability, Piramal Pharma Solutions (PPS) has recently installed a solar power plant at its integrated pharmaceutical site located in Morpeth, United Kingdom. This new solar installation, boasting a capacity of 4.3 MW, is designed to generate renewable energy and aid the company in achieving its ambitious goal of reducing greenhouse gas emissions by 42% by the fiscal year 2030. This initiative exemplifies PPS's dedication not only to its operational efficiency but also to mitigating environmental impact.

Details of the Solar Plant

The solar power plant will produce approximately 3,950 MWh of renewable electricity annually, which equates to around 22% of the site's total electricity consumption. With the installation of approximately 6,200 solar panels over a space of 64,750 square meters, this facility will generate enough clean energy to power about 1,460 households in the UK each year. The project is being realized through a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited, a prominent solar developer and independent power producer.

Environmental Impact

The implementation of this solar energy solution is pivotal as it is estimated to prevent the emission of around 20,000 tonnes of CO₂ equivalent over a 25-year lifespan. Such advancements mark a significant contribution towards Piramal's long-term decarbonization strategy and overall sustainability approach. By bolstering energy resilience through a cost-effective renewable energy solution, Piramal Pharma is asserting its commitment to fostering a low-carbon future.

Statements from Key Figures

Frank Bugg, the Senior Vice President for UK and European Operations at Piramal Pharma Solutions, expressed, "At Piramal Pharma Solutions, we are integrating sustainability principles into every operation and decision across our global network. We are excited to enhance our commitment to decarbonization and renewable energy alongside our partner Alight to bring added value to our clients and shareholders around the world."

Rob Stait, Managing Director at Alight, emphasized the significance of this project: "Across the UK, businesses are seeking tangible ways to reduce their emissions, enhance their energy resilience, and manage long-term energy costs. This project with Piramal Pharma demonstrates how on-site solar installations can address these three challenges effectively."

Future Perspectives

The operational launch of the solar plant is anticipated in the first quarter of 2027, further cementing Piramal Pharma’s commitment to environmental stewardship and sustainable practices in the pharmaceutical sector. This move not only reflects the company’s goals but also its responsive strategy to the growing demands for greener practices in industries worldwide.

About Piramal Pharma Solutions

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end solutions throughout the drug lifecycle. With an integrated network of facilities across North America, Europe, and Asia, Piramal serves its clients with a comprehensive array of services, including drug discovery, process development, clinical trial supplies, and commercial manufacturing of active pharmaceutical ingredients and finished dosage forms. The company is also engaged in specialized services such as the development and production of highly potent active pharmaceutical ingredients, sterile fill/finish, and biologics through its subsidiary Yapan Bio Private Limited.

For more detailed information, visit Piramal Pharma Solutions' official website.

Conclusion

The establishment of the solar plant at Morpeth marks an important milestone for Piramal Pharma Solutions in its journey towards sustainable operations. By investing in renewable energy sources, Piramal not only addresses pressing environmental concerns but also positions itself as a responsible leader in the pharmaceutical industry, dedicated to innovative and sustainable growth.